-
A total of 3, 237 participants fulfilled the eligibility criteria and were included in the analyses (Figure 1). The mean age of the eligible participants (48.7% male) was 53.5 ± 8.6 years, and the mean ALP level was 71.39 ± 20.35 U/L. The characteristics of the eligible participants and the excluded population are presented in Supplementary Table S1 (available in www.besjournal.com). All participants were divided into quintile groups according to their serum ALP levels, and the demographic data and cardiovascular risk factors were compared across the five quintile groups, as presented in Table 1. Participants in the higher ALP quintiles were older, had a higher BMI, and were more likely to have hypertension, diabetes mellitus, and stroke (all P < 0.05). From the lowest to the highest quintile, TC, LDL-C, and TG levels increased, while eGFR and HDL-C levels decreased (all P < 0.05).
Table Supplementary Table S1. Comparison of Characteristics between Included and Excluded Participants
Characteristics Included Population Excluded Population P Value Number 3, 237 1, 383 < 0.0001 Age, year 53.55 ± 8.58 51.89 ± 8.70 < 0.0001 Male, % 1, 576 (48.69) 736 (53.22) 0.0048 BMI, kg/m2 24.97 ± 3.24 25.07 ± 3.53 0.5446 Hypertension, % 760 (23.48) 289 (20.90) 0.0550 Diabetes, % 269 (8.31) 107 (7.74) 0.5139 eGFR, mL·min-1 1.73 m-2 88.18 ± 12.99 90.02 ± 13.28 < 0.0001 Myocardial infarction, % 23 (0.71) 17 (1.23) 0.0814 Stroke, % 87 (2.69) 29 (2.10) 0.2398 Current smoker, % 773 (23.88) 391 (28.27) 0.0016 Heavy alcoholism, % 26 (0.80) 15 (1.08) 0.3503 Total cholesterol, mmol/L 4.71 ± 0.90 4.67 ± 0.91 0.1162 LDL-C, mmol/L 2.65 ± 0.60 2.62 ± 0.63 0.0988 TG, mmol/L 1.73 ± 1.43 1.72 ± 1.48 0.8393 HDL-C, mmol/L 1.21 ± 0.27 1.20 ± 0.28 0.4096 Statins therapy, % 56 (1.73) 16 (1.16) 0.1498 Education level 0.0004 Illiteracy/primary/middle school 1, 035 (31.97) 377 (27.26) High school 1, 049 (32.41) 436 (31.53) College/University 1, 153 (35.62) 570 (41.21) Income, 0.0083 ≤3, 000 1, 605 (49.58) 659 (47.65) 3, 001-5, 000 1, 442 (44.55) 609 (44.03) > 5, 000 190 (5.87) 115 (8.32) ALP level, U/L 71.39 ± 20.35 70.30 ± 24.06 0.0493 Note.ALP: alkaline phosphatase; BMI: body mass index; eGFR: estimated glomerular filtration rate; LDL-C: low density lipoprotein cholesterol; TG: triglyceride; HDL-C: high density lipoprotein cholesterol. Table 1. Demographic and Baseline Clinical Characteristics of the Study Population According to ALP Quintiles
ALP Quintiles Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P Value Number of subjects, n 646 628 690 643 630 / ALP level, U/L 47.28 ± 5.59 59.17 ± 2.50 68.62 ± 2.95 79.76 ± 3.79 102.78 ± 15.94 / Age, year 49.49 ± 7.84 52.84 ± 8.27 53.81 ± 8.19 55.15 ± 8.70 56.50 ± 8.22 < 0.0001 Male, % 230 (35.60) 329 (52.39) 377 (54.64) 333 (51.79) 307 (48.73) < 0.0001 BMI, kg/m2 23.94 ± 3.19 24.87 ± 3.24 25.17 ± 3.05 25.27 ± 3.10 25.61 ± 3.36 < 0.0001 Hypertension, % 96 (14.86) 119 (18.95) 161 (23.33) 171 (26.59) 213 (33.81) < 0.0001 Diabetes, % 31 (4.80) 47 (7.48) 47 (6.81) 64 (9.95) 80 (12.70) < 0.0001 eGFR, mL·min-1 1.73 m-2 90.91 ± 12.75 89.13 ± 11.99 87.86 ± 12.73 87.00 ± 13.34 85.92 ± 13.54 < 0.0001 Myocardial infarction, % 1 (0.15) 7 (1.11) 9 (1.30) 0 (0.00) 6 (0.95) 0.0014 Stroke, % 6 (0.93) 17 (2.71) 24 (3.48) 18 (2.80) 22 (3.49) 0.0279 Current smoker, % 97 (15.02) 146 (23.25) 185 (26.81) 163 (25.35) 182 (28.89) < 0.0001 Heavy alcoholism, % 3 (0.46) 6 (0.96) 9 (1.30) 4 (0.62) 4 (0.63) 0.4370 Total cholesterol, mmol/L 4.52 ± 0.80 4.62 ± 0.85 4.71 ± 0.90 4.85 ± 0.85 4.84 ± 1.03 < 0.0001 LDL-C, mmol/L 2.49 ± 0.56 2.58 ± 0.60 2.67 ± 0.62 2.75 ± 0.58 2.74 ± 0.61 < 0.0001 TG, mmol/L 1.35 ± 0.98 1.65 ± 1.42 1.70 ± 1.16 1.89 ± 1.60 2.06 ± 1.77 < 0.0001 HDL-C, mmol/L 1.28 ± 0.29 1.21 ± 0.26 1.20 ± 0.28 1.19 ± 0.27 1.16 ± 0.25 < 0.0001 Statin therapy, % 10 (1.55) 7 (1.11) 12 (1.74) 9 (1.40) 18 (2.86) 0.1558 Education level < 0.0001 Illiteracy/primary/middle school 122 (18.89) 183 (29.14) 214 (31.01) 255 (39.66) 261 (41.43) High school 221 (34.21) 191 (30.41) 222 (32.17) 206 (32.04) 209 (33.17) College/University 303 (46.90) 254 (40.45) 254 (36.81) 182 (28.30) 160 (25.40) Income, CNY < 0.0001 ≤ 3, 000 267 (41.33) 297 (47.29) 350 (50.72) 356 (55.37) 335 (53.17) 3, 001-5, 000 336 (52.01) 286 (45.54) 301 (43.62) 265 (41.21) 254 (40.32) > 5, 000 43 (6.66) 45 (7.17) 39 (5.65) 22 (3.42) 41 (6.51) Note. ALP: alkaline phosphatase; BMI: body mass index; eGFR: estimated glomerular filtration rate; LDL-C: low-density lipoprotein cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol. -
The mean common carotid IMT values across the ALP quintiles are presented in Table 2. Both sides of the common carotid IMT increased gradually from the lowest to the highest quintiles. Compared with the first quartile (the reference category), the ORs (95% CIs) for abnormal common carotid IMT were 2.14 (1.38-3.32), 2.34 (1.52-3.59), 3.24 (2.14-4.93), and 3.45 (2.27-5.23) for the second, third, fourth, and fifth quintile, respectively (all P < 0.0001). After adjusting for confounders, the ORs for abnormal common carotid IMT in the fourth and fifth quintile were 1.78 (95% CI 1.13-2.82, P = 0.0135) and 1.82 (95% CI: 1.15-2.87, P = 0.0110), respectively (Table 3). In the subgroup analysis, the risk of abnormal IMT per ALP quintile did not differ with respect to sex, age, eGFR, NAFLD, and metabolic syndrome (Supplementary Table S2 available in www.besjournal.com).
Table 2. Comparison of Common Carotid IMT and Carotid Plaque Across different ALP Levels
ALP Quintiles Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P Value Left Mean common carotid IMT, mm 0.69 ± 0.13 0.73 ± 0.16 0.74 ± 0.20 0.76 ± 0.16 0.78 ± 0.18 < 0.0001 Carotid plaque, % 40 (6.19) 67 (10.67) 70 (10.14) 83 (12.91) 102 (16.19) < 0.0001 Right Mean common carotid IMT, mm 0.68 ± 0.13 0.72 ± 0.16 0.73 ± 0.18 0.76 ± 0.20 0.76 ± 0.16 < 0.0001 Carotid plaque, % 29 (4.49) 60 (9.55) 69 (10.00) 78 (12.13) 86 (13.65) < 0.0001 Note.IMT: Intima media thickness; ALP: alkaline phosphatase. Table Supplementary Table 2. Adjusted risks of abnormal common carotid IMT per ALP quintile across different subgroup
Adjusted Odd Ratios 95% Confidence Interval P for Interaction Sex 0.1644 Male 1.09 0.97-1.21 Female 1.26 1.05-1.51 Age 0.3846 < 65 years 1.14 1.03-1.26 ≥ 65 years 1.23 1.00-1.51 Estimated glomerular filtration rate (eGFR) 0.8495 < 50th 1.08 0.96-1.22 ≥ 50th 1.19 1.03-1.38 Nonalcoholic fatty liver disease (NAFLD) 0.8362 Yes 1.13 1.00-1.27 No 1.14 0.98-1.33 Metabolic syndrome 0.2544 Yes 1.10 0.97-1.25 No 1.14 0.99-1.32 -
We examined the correlation of serum ALP levels with carotid plaque and ECAS. As shown in Table 2, the prevalence of carotid plaques increased gradually from the lowest to the highest quintile (from 6.19% to 16.19% on the left side and from 4.49% to 13.65% on the right side, all P < 0.0001). The unadjusted risks of carotid plaques were significantly elevated in the higher quintiles, compared to the reference (the lowest quintile). However, after adjusting for confounding covariates, the association between carotid plaques and ALP quintiles was no longer significant (Table 3). Therefore, our data indicate that there is no significant link between ALP levels and carotid plaques.
Table 3. Risk of Abnormal Common Carotid IMT or Carotid Plaque Across ALP Quintiles
ALP Unadjusted Adjusted OR 95% CI P value OR 95% CI P value Mean common carotid IMT > 0.9 mm Quintile 1 reference - - - - - Quintile 2 2.14 1.38-3.32 0.0007 1.53 0.95-2.47 0.0812 Quintile 3 2.34 1.52-3.59 0.0001 1.47 0.92-2.34 0.1085 Quintile 4 3.24 2.14-4.93 < 0.0001 1.78 1.13-2.82 0.0135 Quintile 5 3.45 2.27-5.23 < 0.0001 1.82 1.15-2.87 0.0110 Carotid plaques Quintile 1 reference - - - - - Quintile 2 1.90 1.34-2.68 0.0003 1.28 0.87-1.88 0.2072 Quintile 3 1.92 1.37-2.70 0.0002 1.12 0.77-1.64 0.5438 Quintile 4 2.45 1.75-3.41 < 0.0001 1.23 0.84-1.78 0.2895 Quintile 5 2.77 1.99-3.85 < 0.0001 1.27 0.88-1.85 0.2071 Note.The lowest quintile (quintile 5) was used as the reference. IMT: Intima media thickness; ALP: alkaline phosphatase; OR: odds ratio; CI: confidence interval. Using the first ALP quintile as the reference, we found that the ORs for ECAS in the second, third, fourth, and fifth quintile were 1.77 (95% CI: 1.34-2.33), 1.65 (95% CI: 1.25-2.18), 1.880 (95% CI: 1.43-2.48), and 2.47 (95% CI: 1.88-3.23), respectively. In addition, the OR for ECAS in the fifth quintile was 1.47 (95% CI: 1.09-1.97, P = 0.0106) after adjusting for age, sex, BMI, hypertension, diabetes mellitus, eGFR, myocardial infarction, stroke, smoking, alcohol drinking, lipid profile, education level, family income, and statin therapy (Table 4).
Table 4. Risk of ECAS Across different ALP Quintiles
ALP Unadjusted Adjusted OR 95% CI P value OR 95% CI P value Quintile 1 reference - - reference - - Quintile 2 1.77 1.34-2.33 < 0.0001 1.30 0.96-1.74 0.0864 Quintile 3 1.65 1.25-2.18 0.0004 1.11 0.83-1.49 0.4896 Quintile 4 1.88 1.43-2.48 < 0.0001 1.20 0.90-1.62 0.2180 Quintile 5 2.47 1.88-3.23 < 0.0001 1.47 1.09-1.97 0.0106 Note. ALP: alkaline phosphatase; OR: odds ratio; CI: confidence interval; ECAS: extracranial carotid artery stenosis.
doi: 10.3967/bes2019.059
Association between Serum Alkaline Phosphatase and Carotid Atherosclerosis in a Chinese Population: A Community-based Cross-sectional Study
-
Abstract:
Objective This study aimed to investigate the relationship between alkaline phosphatase (ALP) and common carotid intima media thickness (IMT), carotid plaque, and extracranial carotid artery stenosis (ECAS). Methods A total of 3, 237 participants aged ≥ 40 years were recruited from Jidong community in 2013-2014. Participants were divided into five quintile groups based on their serum ALP levels. Carotid atherosclerosis was assessed using ultrasound. Abnormal IMT, carotid plaque, and ECAS were defined as IMT > 0.9 mm, IMT > 1.5 mm, and ≥ 50% stenosis in at least one extracranial carotid artery, respectively. Results Common carotid IMT values and the prevalence of carotid plaque increased across serum ALP quintiles. Higher ALP quintiles were correlated with an increased risk of abnormal IMT[fourth quintile:odds ratio (OR) 1.78, 95% confidence interval (CI) 1.13-2.82, P=0.0135; fifth quintile:OR=1.82, 95% CI:1.15-2.87, P=0.0110] and ECAS compared to the lowest quintile (fifth quintile:OR=1.47, 95% CI:1.09-1.97, P=0.0106). The association between ALP and prevalence of carotid plaque became insignificant after adjustment for confounders. Conclusion Serum ALP levels were independently associated with abnormal common carotid IMT and ECAS. These conclusions need to be further corroborated in future prospective cohort studies. -
Supplementary Table S1. Comparison of Characteristics between Included and Excluded Participants
Characteristics Included Population Excluded Population P Value Number 3, 237 1, 383 < 0.0001 Age, year 53.55 ± 8.58 51.89 ± 8.70 < 0.0001 Male, % 1, 576 (48.69) 736 (53.22) 0.0048 BMI, kg/m2 24.97 ± 3.24 25.07 ± 3.53 0.5446 Hypertension, % 760 (23.48) 289 (20.90) 0.0550 Diabetes, % 269 (8.31) 107 (7.74) 0.5139 eGFR, mL·min-1 1.73 m-2 88.18 ± 12.99 90.02 ± 13.28 < 0.0001 Myocardial infarction, % 23 (0.71) 17 (1.23) 0.0814 Stroke, % 87 (2.69) 29 (2.10) 0.2398 Current smoker, % 773 (23.88) 391 (28.27) 0.0016 Heavy alcoholism, % 26 (0.80) 15 (1.08) 0.3503 Total cholesterol, mmol/L 4.71 ± 0.90 4.67 ± 0.91 0.1162 LDL-C, mmol/L 2.65 ± 0.60 2.62 ± 0.63 0.0988 TG, mmol/L 1.73 ± 1.43 1.72 ± 1.48 0.8393 HDL-C, mmol/L 1.21 ± 0.27 1.20 ± 0.28 0.4096 Statins therapy, % 56 (1.73) 16 (1.16) 0.1498 Education level 0.0004 Illiteracy/primary/middle school 1, 035 (31.97) 377 (27.26) High school 1, 049 (32.41) 436 (31.53) College/University 1, 153 (35.62) 570 (41.21) Income, 0.0083 ≤3, 000 1, 605 (49.58) 659 (47.65) 3, 001-5, 000 1, 442 (44.55) 609 (44.03) > 5, 000 190 (5.87) 115 (8.32) ALP level, U/L 71.39 ± 20.35 70.30 ± 24.06 0.0493 Note.ALP: alkaline phosphatase; BMI: body mass index; eGFR: estimated glomerular filtration rate; LDL-C: low density lipoprotein cholesterol; TG: triglyceride; HDL-C: high density lipoprotein cholesterol. Table 1. Demographic and Baseline Clinical Characteristics of the Study Population According to ALP Quintiles
ALP Quintiles Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P Value Number of subjects, n 646 628 690 643 630 / ALP level, U/L 47.28 ± 5.59 59.17 ± 2.50 68.62 ± 2.95 79.76 ± 3.79 102.78 ± 15.94 / Age, year 49.49 ± 7.84 52.84 ± 8.27 53.81 ± 8.19 55.15 ± 8.70 56.50 ± 8.22 < 0.0001 Male, % 230 (35.60) 329 (52.39) 377 (54.64) 333 (51.79) 307 (48.73) < 0.0001 BMI, kg/m2 23.94 ± 3.19 24.87 ± 3.24 25.17 ± 3.05 25.27 ± 3.10 25.61 ± 3.36 < 0.0001 Hypertension, % 96 (14.86) 119 (18.95) 161 (23.33) 171 (26.59) 213 (33.81) < 0.0001 Diabetes, % 31 (4.80) 47 (7.48) 47 (6.81) 64 (9.95) 80 (12.70) < 0.0001 eGFR, mL·min-1 1.73 m-2 90.91 ± 12.75 89.13 ± 11.99 87.86 ± 12.73 87.00 ± 13.34 85.92 ± 13.54 < 0.0001 Myocardial infarction, % 1 (0.15) 7 (1.11) 9 (1.30) 0 (0.00) 6 (0.95) 0.0014 Stroke, % 6 (0.93) 17 (2.71) 24 (3.48) 18 (2.80) 22 (3.49) 0.0279 Current smoker, % 97 (15.02) 146 (23.25) 185 (26.81) 163 (25.35) 182 (28.89) < 0.0001 Heavy alcoholism, % 3 (0.46) 6 (0.96) 9 (1.30) 4 (0.62) 4 (0.63) 0.4370 Total cholesterol, mmol/L 4.52 ± 0.80 4.62 ± 0.85 4.71 ± 0.90 4.85 ± 0.85 4.84 ± 1.03 < 0.0001 LDL-C, mmol/L 2.49 ± 0.56 2.58 ± 0.60 2.67 ± 0.62 2.75 ± 0.58 2.74 ± 0.61 < 0.0001 TG, mmol/L 1.35 ± 0.98 1.65 ± 1.42 1.70 ± 1.16 1.89 ± 1.60 2.06 ± 1.77 < 0.0001 HDL-C, mmol/L 1.28 ± 0.29 1.21 ± 0.26 1.20 ± 0.28 1.19 ± 0.27 1.16 ± 0.25 < 0.0001 Statin therapy, % 10 (1.55) 7 (1.11) 12 (1.74) 9 (1.40) 18 (2.86) 0.1558 Education level < 0.0001 Illiteracy/primary/middle school 122 (18.89) 183 (29.14) 214 (31.01) 255 (39.66) 261 (41.43) High school 221 (34.21) 191 (30.41) 222 (32.17) 206 (32.04) 209 (33.17) College/University 303 (46.90) 254 (40.45) 254 (36.81) 182 (28.30) 160 (25.40) Income, CNY < 0.0001 ≤ 3, 000 267 (41.33) 297 (47.29) 350 (50.72) 356 (55.37) 335 (53.17) 3, 001-5, 000 336 (52.01) 286 (45.54) 301 (43.62) 265 (41.21) 254 (40.32) > 5, 000 43 (6.66) 45 (7.17) 39 (5.65) 22 (3.42) 41 (6.51) Note. ALP: alkaline phosphatase; BMI: body mass index; eGFR: estimated glomerular filtration rate; LDL-C: low-density lipoprotein cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol. Table 2. Comparison of Common Carotid IMT and Carotid Plaque Across different ALP Levels
ALP Quintiles Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P Value Left Mean common carotid IMT, mm 0.69 ± 0.13 0.73 ± 0.16 0.74 ± 0.20 0.76 ± 0.16 0.78 ± 0.18 < 0.0001 Carotid plaque, % 40 (6.19) 67 (10.67) 70 (10.14) 83 (12.91) 102 (16.19) < 0.0001 Right Mean common carotid IMT, mm 0.68 ± 0.13 0.72 ± 0.16 0.73 ± 0.18 0.76 ± 0.20 0.76 ± 0.16 < 0.0001 Carotid plaque, % 29 (4.49) 60 (9.55) 69 (10.00) 78 (12.13) 86 (13.65) < 0.0001 Note.IMT: Intima media thickness; ALP: alkaline phosphatase. Supplementary Table 2. Adjusted risks of abnormal common carotid IMT per ALP quintile across different subgroup
Adjusted Odd Ratios 95% Confidence Interval P for Interaction Sex 0.1644 Male 1.09 0.97-1.21 Female 1.26 1.05-1.51 Age 0.3846 < 65 years 1.14 1.03-1.26 ≥ 65 years 1.23 1.00-1.51 Estimated glomerular filtration rate (eGFR) 0.8495 < 50th 1.08 0.96-1.22 ≥ 50th 1.19 1.03-1.38 Nonalcoholic fatty liver disease (NAFLD) 0.8362 Yes 1.13 1.00-1.27 No 1.14 0.98-1.33 Metabolic syndrome 0.2544 Yes 1.10 0.97-1.25 No 1.14 0.99-1.32 Table 3. Risk of Abnormal Common Carotid IMT or Carotid Plaque Across ALP Quintiles
ALP Unadjusted Adjusted OR 95% CI P value OR 95% CI P value Mean common carotid IMT > 0.9 mm Quintile 1 reference - - - - - Quintile 2 2.14 1.38-3.32 0.0007 1.53 0.95-2.47 0.0812 Quintile 3 2.34 1.52-3.59 0.0001 1.47 0.92-2.34 0.1085 Quintile 4 3.24 2.14-4.93 < 0.0001 1.78 1.13-2.82 0.0135 Quintile 5 3.45 2.27-5.23 < 0.0001 1.82 1.15-2.87 0.0110 Carotid plaques Quintile 1 reference - - - - - Quintile 2 1.90 1.34-2.68 0.0003 1.28 0.87-1.88 0.2072 Quintile 3 1.92 1.37-2.70 0.0002 1.12 0.77-1.64 0.5438 Quintile 4 2.45 1.75-3.41 < 0.0001 1.23 0.84-1.78 0.2895 Quintile 5 2.77 1.99-3.85 < 0.0001 1.27 0.88-1.85 0.2071 Note.The lowest quintile (quintile 5) was used as the reference. IMT: Intima media thickness; ALP: alkaline phosphatase; OR: odds ratio; CI: confidence interval. Table 4. Risk of ECAS Across different ALP Quintiles
ALP Unadjusted Adjusted OR 95% CI P value OR 95% CI P value Quintile 1 reference - - reference - - Quintile 2 1.77 1.34-2.33 < 0.0001 1.30 0.96-1.74 0.0864 Quintile 3 1.65 1.25-2.18 0.0004 1.11 0.83-1.49 0.4896 Quintile 4 1.88 1.43-2.48 < 0.0001 1.20 0.90-1.62 0.2180 Quintile 5 2.47 1.88-3.23 < 0.0001 1.47 1.09-1.97 0.0106 Note. ALP: alkaline phosphatase; OR: odds ratio; CI: confidence interval; ECAS: extracranial carotid artery stenosis. -
[1] Targher G, Byrne CD. Circulating markers of liver function and cardiovascular disease risk. Arterioscler Thromb Vasc Biol, 2015; 35, 2290-6. doi: 10.1161/ATVBAHA.115.305235 [2] Sharma U, Pal D, Prasad R. Alkaline phosphatase:An overview. Indian J Clin Biochem, 2014; 29, 269-78. doi: 10.1007/s12291-013-0408-y [3] Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol, 2008; 19, 2193-203. doi: 10.1681/ASN.2008010014 [4] Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant, 2009; 24, 1506-23. doi: 10.1093/ndt/gfn613 [5] Kunutsor SK, Apekey TA, Khan H. Liver enzymes and risk of cardiovascular disease in the general population:A meta-analysis of prospective cohort studies. Atherosclerosis, 2014; 236, 7-17. doi: 10.1016/j.atherosclerosis.2014.06.006 [6] Kim J, Song TJ, Song D, et al. Serum alkaline phosphatase and phosphate in cerebral atherosclerosis and functional outcomes after cerebral infarction. Stroke, 2013; 44, 3547-9. doi: 10.1161/STROKEAHA.113.002959 [7] Park JB, Kang DY, Yang HM, et al. Serum alkaline phosphatase is a predictor of mortality, myocardial infarction, or stent thrombosis after implantation of coronary drug-eluting stent. Eur Heart J, 2013; 34, 920-31. doi: 10.1093/eurheartj/ehs419 [8] Bots ML, Grobbee DE. Intima media thickness as a surrogate marker for generalised atherosclerosis. Cardiovasc Drugs Ther, 2002; 16, 341-51. doi: 10.1023/A:1021738111273 [9] de Groot E, Hovingh GK, Wiegman A, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation, 2004; 109, Ⅲ33-8. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=WK_LWW201705250313811 [10] Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction:The rotterdam study. Circulation, 1997; 96, 1432-7. doi: 10.1161/01.CIR.96.5.1432 [11] O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. N Engl J Med, 1999; 340, 14-22. doi: 10.1056/NEJM199901073400103 [12] Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events:A meta-analysis. Atherosclerosis, 2012; 220, 128-33. doi: 10.1016/j.atherosclerosis.2011.06.044 [13] Wald DS, Bestwick JP, Morton G, et al. Combining carotid intima-media thickness with carotid plaque on screening for coronary heart disease. J Med Screen, 2009; 16, 155-9. doi: 10.1258/jms.2009.009039 [14] Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension:The task force for the management of arterial hypertension of the european society of hypertension (esh) and of the european society of cardiology (esc). Eur Heart J, 2007; 28, 1462-536. [15] Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice:Executive summary. Fourth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil, 2007; 14, E1-40. doi: 10.1097/01.hjr.0000277984.31558.c4 [16] Man E, Cheung PT, Cheung YF. Associations between arterial structure and function and serum levels of liver enzymes in obese adolescents. J Paediatr Child Health, 2017; 53, 691-7. doi: 10.1111/jpc.2017.53.issue-7 [17] Schutte R, Huisman HW, Malan L, et al. Alkaline phosphatase and arterial structure and function in hypertensive african men:The sabpa study. Int J Cardiol, 2013; 167, 1995-2001. doi: 10.1016/j.ijcard.2012.05.035 [18] Gheissari A, Sirous M, Hajzargarbashi T, et al. Carotid intima-media thickness in children with end-stage renal disease on dialysis. Indian J Nephrol, 2010; 20, 29-33. doi: 10.4103/0971-4065.62095 [19] Yang Y, Han X, Chen Y, et al. Association between modifiable lifestyle and the prevalence of atrial fibrillation in a chinese population:Based on the cardiovascular health score. Clin cardiol, 2017; 40, 1061-7. doi: 10.1002/clc.2017.40.issue-11 [20] Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med, 2009; 150, 604-12. doi: 10.7326/0003-4819-150-9-200905050-00006 [21] Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th european stroke conferences, mannheim, germany, 2004, brussels, belgium, 2006, and hamburg, germany, 2011. Cerebrovasc Dis, 2012; 34, 290-6. [22] Grant EG, Benson CB, Moneta GL, et al. Carotid artery stenosis:Grayscale and doppler ultrasound diagnosis——society of radiologists in ultrasound consensus conference. Ultrasound Q, 2003; 19, 190-8. doi: 10.1097/00013644-200312000-00005 [23] Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel ⅲ). JAMA, 2001; 285, 2486-97. doi: 10.1001/jama.285.19.2486 [24] Alberti KG, Zimmet P, Shaw J. Metabolic syndrome——a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med, 2006; 23, 469-80. doi: 10.1111/dme.2006.23.issue-5 [25] Li JW, Xu C, Fan Y, et al. Can serum levels of alkaline phosphatase and phosphate predict cardiovascular diseases and total mortality in individuals with preserved renal function? A systemic review and meta-analysis. PloS One, 2014; 9, e102276. doi: 10.1371/journal.pone.0102276 [26] Haarhaus M, Brandenburg V, Kalantar-Zadeh K, et al. Alkaline phosphatase:A novel treatment target for cardiovascular disease in ckd. Nature reviews. Nephrology, 2017; 13, 429-42. [27] Filipowicz R, Greene T, Wei G, et al. Associations of serum skeletal alkaline phosphatase with elevated c-reactive protein and mortality. Clin J Am Soc Nephrol, 2013; 8, 26-32. doi: 10.2215/CJN.12031111 [28] Kunutsor SK, Bakker SJ, Kootstra-Ros JE, et al. Serum alkaline phosphatase and risk of incident cardiovascular disease:Interrelationship with high sensitivity c-reactive protein. PloS One, 2015; 10, e0132822. doi: 10.1371/journal.pone.0132822 [29] Lencel P, Delplace S, Hardouin P, et al. Tnf-alpha stimulates alkaline phosphatase and mineralization through ppargamma inhibition in human osteoblasts. Bone, 2011; 48, 242-9. doi: 10.1016/j.bone.2010.09.001 [30] Aghagolzadeh P, Bachtler M, Bijarnia R, et al. Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-alpha. Atherosclerosis, 2016; 251, 404-14. doi: 10.1016/j.atherosclerosis.2016.05.044 [31] Shioi A, Katagi M, Okuno Y, et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells:Roles of tumor necrosis factor-alpha and oncostatin m derived from macrophages. Circ Res, 2002; 91, 9-16. doi: 10.1161/01.RES.0000026421.61398.F2 [32] Perticone F, Perticone M, Maio R, et al. Serum alkaline phosphatase negatively affects endothelium-dependent vasodilation in naive hypertensive patients. Hypertension, 2015; 66, 874-80. doi: 10.1161/HYPERTENSIONAHA.115.06117 [33] Savinov AY, Salehi M, Yadav MC, et al. Transgenic overexpression of tissue-nonspecific alkaline phosphatase (tnap) in vascular endothelium results in generalized arterial calcification. J Am Heart Assoc, 2015; 4, pii:e002499. [34] Motamed N, Rabiee B, Poustchi H, et al. Non-alcoholic fatty liver disease (nafld) and 10-year risk of cardiovascular diseases. Clin Res Hepatol Gastroenterol, 2017; 41, 31-8. doi: 10.1016/j.clinre.2016.07.005 [35] Wu S, Wu F, Ding Y, et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events:A systematic review and meta-analysis. Sci Rep, 2016; 6, 33386. doi: 10.1038/srep33386 [36] Al Mheid I, Patel RS, Tangpricha V, et al. Vitamin d and cardiovascular disease:Is the evidence solid? Eur Heart J, 2013; 34, 3691-8. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1177/000992287000900705 [37] Kassi E, Adamopoulos C, Basdra EK, et al. Role of vitamin d in atherosclerosis. Circulation, 2013; 128, 2517-31. doi: 10.1161/CIRCULATIONAHA.113.002654 [38] Wong MS, Delansorne R, Man RY, et al. Vitamin d derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol, 2008; 295, H289-96. doi: 10.1152/ajpheart.00116.2008 [39] Andrukhova O, Slavic S, Zeitz U, et al. Vitamin d is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol Endocrinol, 2014; 28, 53-64. doi: 10.1210/me.2013-1252 [40] Li YC, Kong J, Wei M, et al. 1, 25-dihydroxyvitamin d(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest, 2002; 110, 229-38. doi: 10.1172/JCI0215219 [41] Sung CC, Liao MT, Lu KC, et al. Role of vitamin d in insulin resistance. J Biomed Biotechnol, 2012; 2012, 634195. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_3440067 [42] Al Mheid I, Quyyumi AA. Vitamin d and cardiovascular disease:Controversy unresolved. J Am Coll Cardiol, 2017; 70, 89-100. doi: 10.1016/j.jacc.2017.05.031 [43] Bolland MJ, Grey A, Gamble GD, et al. Calcium and vitamin d supplements and health outcomes:A reanalysis of the women's health initiative (whi) limited-access data set. Am J Clin Nutr, 2011; 94, 1144-9. doi: 10.3945/ajcn.111.015032